Assessing Protein And Payload Stability Of Antibody Drug Conjugate Brentuximab Vedotin In Monkey Plasma

By Andrea Ngai and Muhammed Naqvi, Amador Bioscience, and Xi Qiu and Kenda L.J. Evans, Agilent Technologies, Inc.

Quantifying both the protein and cytotoxic payload of antibody–drug conjugates in complex biological matrices remains a persistent analytical challenge. A streamlined workflow combines automated purification with high-sensitivity LC/MS detection to track brentuximab vedotin stability in monkey plasma over time. Automated liquid handling reduces variability during sample preparation, while advanced LC/MS platforms enable precise measurement of both intact protein and released payload. Together, these capabilities provide a clearer view of how each component behaves under physiological conditions. Such insight is critical for refining ADC design, improving stability profiles, and informing clinical development decisions.

Take a look at how integrating automation and targeted quantification can strengthen confidence in your biotherapeutic analysis strategy.